Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has signed a contract manufacturing agreement (CMO) worth KRW 294.9B (8.29% of recent annual revenue) with a global pharmaceutical company.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Conclusion of Single Sales / Supply Contract
- Contract Type & Name: Other Sales/Supply Contract / Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 294,921,000,000 (approx. KRW 294.9B)
- Exchange Rate Applied: Initial basic exchange rate on March 16, 2026 (USD/KRW 1,489.50)
- Scalability: May increase up to KRW 375,354,000,000 (approx. KRW 375.4B) upon counterparty’s request
- Recent Annual Revenue: KRW 3,557,303,554,371 (Based on FY2024 consolidated financial statements)
- Contract-to-Revenue Ratio: 8.29%
- Contract Counterparty: Global Pharmaceutical Company (Name withheld for business confidentiality until December 31, 2029)
- Contract Period: March 16, 2026 ~ December 31, 2029 (Actual supply scheduled to begin in Q1 2027)
- Contract Date: March 16, 2026
- Key Terms: Down payment / Advance payment: None
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Supply Commencement in Q1 2027 and Contract Execution Progress
This disclosure details Celltrion’s KRW 294.9B pharmaceutical contract manufacturing agreement with a global pharmaceutical company, making it important to monitor the commencement of actual supply starting in Q1 2027. Tracking the start of deliveries according to schedule is essential to verify contract fulfillment. Execution updates and supply status can be verified through upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports) or subsequent regulatory disclosures.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
